Help is on the Way as Rising Alzheimer's Cases Highlight Urgency for New Treatments

Stock Information for Marvel Biosciences Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Marvel Biosciences Corp.

Marvel Biosciences Announces Closing of Private Placement
Marvel Biosciences Announces Closing of Second Tranche of Private Placement
Marvel Announces the Second of Two Final Data Sets from Rett Syndrome Study: MB-204 Significantly Outperforms Trofinetide Following Cessation of Drug Treatment
Marvel Biosciences to Give Oral Presentation at The Annual IRSF Rett Syndrome Scientific Meeting
Marvel Biosciences Selected to Present Alzheimer's Research at the 2025 Alzheimer's Association International Conference
Marvel Biosciences Announces Private Placement
Marvel to File for Orphan Drug Designation with The U.S. FDA for MB-204 as a Treatment for Rett Syndrome
Marvel Announces First of Two Final Data Sets from Rett Syndrome Study: MB-204 Significantly Outperforms Trofinetide

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.